Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884196 | 0.89 | AR (0.46) | PLA2G2AS1PR3 | |
| SCHEMBL1897486 | 0.80 | S1PR3 (0.66) | S1PR3 | |
| SCHEMBL1876291 | 0.73 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL1884573 | 0.72 | NOTUM (0.47) | AGTR1AGTR2 | |
| SCHEMBL12638315 | 0.71 | AR (0.47) | PLA2G2AS1PR3 | |
| SCHEMBL337115 | 0.70 | S1PR3 (0.61) | S1PR3 | |
| SCHEMBL28803583 | 0.70 | POLB (0.50) | SMN1; SMN2LMNATSHR | |
| SCHEMBL1882164 | 0.70 | AR (0.46) | PLA2G2AS1PR3 | |
| SCHEMBL1876284 | 0.70 | AR (0.46) | LMNAPLA2G2AS1PR3 | |
| SCHEMBL12672146 | 0.69 | S1PR3 (0.71) | S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2185506-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | MEN1 3298/4885KMT2A 4539/4885SMN1; SMN2 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.